Good news from the world of scientific research: The mRNA vaccine could be crucial in the fight against cancer. Word, or rather, study by Paolo Ascierto, a Neapolitan oncologist who has also given so much in the pandemic challenge.
The research in question could put the cards on the table in our favor.
Internet.tuttogratis.it
During the pandemic crisis, knowledge of the Vaccine using mRNA technology. Research could provide a guarantee of how this type of vaccine combined with the immunotherapy drug pembrolizumab can limit the risk of recurrence to 44%. A great announcement for the fight against cancer.
Vaccination and fight against tumors, the study of Paolo Ascierto
If the results of the second phase trials are confirmed, it will be good news not only for melanoma patients but also for those facing other types of cancer.
This was said by Paul AsciertoPresident of the Melanoma Foundation and Head of the Department of Melanoma Oncology, Oncological Immunotherapy and Innovative Therapies of the Pascale Institute in Naples, during a meeting with Ansa.
The Neapolitan oncologist illustrated how the conclusions of the second phase of the study came about the potential of a new mRNA vaccine being manufactured by Moderna (currently known as mRNA-4157/V940) in combination with the immunotherapy drug pembrolizumab from reduce the likelihood of recurrence by 44% compared to immunotherapy alone.
Individual care for each patient
The President of the Melanoma Foundation remembers how much The founding technology of the new therapeutic vaccine is the same as that used to contain the Covid.
Although in this case we are dealing with a Process with innovative colors focused ever since Personalization of the vaccine for each individual patient, as stated by Ascierto himself. The same applies to other oncological pathologies.
Therefore, definitive approval of the melanoma results would be wonderful news for any cancer patient.
The third phase of the research will start next year, as the oncologist from the Pascale Institute of Naples finally explained:
Typically it can take 3 to 5 years from enrollment to first date.
We await with hope and best wishes that scientific research can add another important step to this impassable path. We are with you.
The information in the article is for informational purposes only and relates to scientific studies published in medical journals. Therefore, they are not a substitute for medical or specialist advice and should not be considered in formulating any treatment or diagnosis.